GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL
GlaxoSmithKline CEO Emma Walmsley is working on rebuilding the pharma giant’s R&D operation with some of the best minds in the business. But in the meantime, she can rely on repeated setbacks among her rivals to win some badly needed breathing room.
Case in point: Wednesday evening Mylan reported that the FDA had kicked back its copycat version of Advair, again. This follows a whole slate of rejections for companies looking to grab the mega-blockbuster franchise away with cheaper copies of the respiratory drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.